Search
EHA-THD joint membership
Save money and time by becoming a joint member of EHA and the Türk Hematoloji Derneği. We've joined forces with the Türk Hematoloji Derneği (THD) to offer a special joint membership deal.
Read moreCompliance and reports
EHA is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.
Read moreEHA Diagnosis
EHA Diagnosis is a new digital tool that EHA has created exclusively for our members.
Read moreApply to be a Master Class mentor
Applications closed on July 15, 2024. There are two types of Master Class mentor: junior mentor and senior mentor. Before you apply, make sure you've read and understood the relevant eligibility criteria.
Read moreApply to be a Master Class mentee
Applications closed on July 15, 2024
EligibilityTo apply to be a menteee, you must be one of the following:
A hematologist
Receiving hematology training
Seeing hematology patients
You must also be an EHA member.
Abstract & Clinical Case Submission and Travel Grant
Submit your abstract here
Abstract and clinical case procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time…
Membership
Boost your career, fast-track your development, and make new connections by joining a pioneering European hematology organization with global reach.
Read moreCall for interest — new La Cantera event
The call for interest is closed at 23:59 on November 30, 2024. In 2025, EHA will provide funding for a new La Cantera coaching event.
Read moreSpecialized Working Group Grants
The call for grant proposals closed at 12:00 on November 30, 2024. EHA provides financial support to small research projects initiated by our specialized working groups (SWGs).
Read moreI4MDS consortium: advancing MDS treatment and understanding
The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- »